These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 8196467

  • 21. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM, Faulds D.
    Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
    [Abstract] [Full Text] [Related]

  • 22. Lansoprazole: a proton pump inhibitor.
    Garnett WR.
    Ann Pharmacother; 1996 Dec; 30(12):1425-36. PubMed ID: 8968456
    [Abstract] [Full Text] [Related]

  • 23. [Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
    Kayser S, Flury R, Zbinden R, Fried M, Wirth HP.
    Schweiz Med Wochenschr; 1997 Apr 26; 127(17):722-7. PubMed ID: 9221483
    [Abstract] [Full Text] [Related]

  • 24. Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer.
    Avner DL, Movva R, Nelson KJ, McFarland M, Berry W, Erfling W.
    Am J Gastroenterol; 1995 Aug 26; 90(8):1289-94. PubMed ID: 7639232
    [Abstract] [Full Text] [Related]

  • 25. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
    Hirschowitz BI, Mohnen J, Shaw S.
    Aliment Pharmacol Ther; 1996 Aug 26; 10(4):497-506. PubMed ID: 8853753
    [Abstract] [Full Text] [Related]

  • 26. [Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole].
    Müller P, Fuchs W, Peifer-Weiss A, Simon B.
    Fortschr Med; 1998 Oct 10; 116(28):31-2. PubMed ID: 9844264
    [No Abstract] [Full Text] [Related]

  • 27. [Strong inhibition of gastric acid secretion: when is it justifiable?].
    Dobrilla G, Amplaz S, Benvenuti S, Bertozzo A.
    G Clin Med; 1990 Oct 10; 71(8-9):521-6. PubMed ID: 1980653
    [No Abstract] [Full Text] [Related]

  • 28. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
    Timmer W, Ripke H, Kleist P, Ehrlich A, Wieckhorst G, Lücker PW, Fuder H.
    Methods Find Exp Clin Pharmacol; 1995 Sep 10; 17(7):489-95. PubMed ID: 8577212
    [Abstract] [Full Text] [Related]

  • 29. Omeprazole: a comprehensive review.
    Massoomi F, Savage J, Destache CJ.
    Pharmacotherapy; 1993 Sep 10; 13(1):46-59. PubMed ID: 8437967
    [Abstract] [Full Text] [Related]

  • 30. Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
    Kawano S, Murakami M, Saita H, Tsuji S.
    J Gastroenterol; 1996 Nov 10; 31 Suppl 9():41-3. PubMed ID: 8959517
    [Abstract] [Full Text] [Related]

  • 31. Continuous maintenance with low-dose lansoprazole versus Helicobacter pylori eradication in the prevention of duodenal ulcer recurrence.
    Parente F, Bargiggia S, Bollani S, Colombo E, Bianchi Porro G.
    Hepatogastroenterology; 1998 Nov 10; 45(22):990-3. PubMed ID: 9755995
    [Abstract] [Full Text] [Related]

  • 32. [Anti-H2 and omeprazole in brief therapy of peptic ulcer].
    Piai G, Sabbatini F, Mazzacca G.
    Ann Ital Chir; 1990 Nov 10; 61(1):11-4. PubMed ID: 1978622
    [No Abstract] [Full Text] [Related]

  • 33. Lansoprazole versus omeprazole in the treatment of reflux esophagitis.
    Vcev A, Stimac D, Vceva A, Rubinić M, Ivandić A, Ivanis N, Horvat D, Volarić M, Karner I.
    Acta Med Croatica; 1997 Nov 10; 51(3):171-4. PubMed ID: 9248117
    [Abstract] [Full Text] [Related]

  • 34. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
    Russo A, Dattilo M.
    Ital J Gastroenterol Hepatol; 1997 Aug 10; 29(4):312-9. PubMed ID: 9476183
    [Abstract] [Full Text] [Related]

  • 35. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD, Wilde MI.
    Drugs; 1997 Sep 10; 54(3):473-500. PubMed ID: 9279507
    [Abstract] [Full Text] [Related]

  • 36. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
    Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Haber M.
    Am J Gastroenterol; 1996 Sep 10; 91(9):1758-65. PubMed ID: 8792694
    [Abstract] [Full Text] [Related]

  • 37. Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study.
    Gupta VK, Dhar A, Srinivasan S, Rattan A, Sharma MP.
    Am J Gastroenterol; 1997 Jul 10; 92(7):1140-2. PubMed ID: 9219786
    [Abstract] [Full Text] [Related]

  • 38. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study.
    Lamouliatte H, Cayla R, Zerbib F, Forestier S, de Mascarel A, Joubert-Collin M, Mégraud F.
    Am J Gastroenterol; 1998 Sep 10; 93(9):1531-4. PubMed ID: 9732938
    [Abstract] [Full Text] [Related]

  • 39. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
    Güliter S, Keleş H, Ozkurt ZN, Cengiz DU, Kolukisa E.
    Turk J Gastroenterol; 2005 Mar 10; 16(1):29-33. PubMed ID: 16252185
    [Abstract] [Full Text] [Related]

  • 40. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK.
    Am J Med; 2005 Nov 10; 118(11):1271-8. PubMed ID: 16271912
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.